A pharmaceutical industry leader recognized for building R&D and service capabilities, delivering
research and early development portfolios of drug candidates, and establishing R&D partnerships in
US, Europe, China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice
President and Head of Asia and Emerging Markets iMed at AstraZeneca, and served as Vice President
and Head of Asia R&D at Pfizer and as Executive Director and head of Pfizer's global R&D strategic
management group. Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of
California, San Francisco.
Tao Guo, Ph.D
Vice President, Head of International Discovery Service Unit
Over 20 years’ experience in organic/medicinal chemistry, formerly Director of Chemistry at
Pharmacopeia. B.S. in Chemistry from Peking University, Ph.D in Organic Chemistry from
Columbia University, and postdoctoral fellow in Bioorganic Chemistry at UC Berkeley.
Qunsheng Ji, Ph.D
Vice President, Head of Oncology and Immunology Unit
Over 15 years of industry experience in drug discovery and translational science especially
in oncology and recently renal diseases. Ph.D from Chinese Academy of Medical Science/
Peking Union Medical College, jointed with Vanderbilt University USA, Medical degree from
First Military Medical University in Guangzhou.
Henry Lu, Ph.D
Vice President, Head of Biology
Over 20 years’ experience in biological research and pharmaceutical industry. Formerly
Adjunct Associate Professor at the University of California San Francisco, Senior Director
of Infectious Diseases at Rigel Pharmaceuticals Inc. B.S. from Fudan University, Ph.D from
the Shanghai Institute of Biochemistry, Academia Sinica.
Baoning Su, Ph.D
Vice President, Head of Core Analytical Services (CAS) Unit
Over 20 years working experience in the areas of natural products and pharmaceutical
analyses, formerly Senior Research Investigator at Bristol-Myers Squibb. Ph.D in Organic
Chemistry from Lanzhou University.
Xuanjia Peng, Ph.D
Vice President, Head of HitS unit
Over 15 years’ experience in organic/medicinal chemistry, rich experience on small molecule
drug discovery and successively led the medicinal chemistry group, CSU operation team,
LabNetwork team, and DWL team to achieve rapid growth and empower numerous clients from
small start-ups to world-class global customers.
Xuehai Tan, Ph.D
Senior Vice President, Founder, CEO & President of HD Biosciences
A founder of HD Biosciences and over 30 years’ experience in Drug Discovery. Ph.D in
Biochemistry and Molecular Biology from Medical University of Ohio, post-doc and assistant
professor at University of Washington. Formerly worked in Johnson & Johnson, Aurora
Biosciences, and founded HD Biosciences in 2002.
Declan Ryan, Ph.D
Vice President, US Business Development
Over 20 years' experience in R&D in both research and business development roles at
3-Dimensional Pharmaceuticals, Novartis, Johnson & Johnson, AMRI and Shanghai ChemPartner.
Ph.D from University of Lausanne, Switzerland and Post-doc studies at Yale University and
University of Pittsburgh, USA.
Dave Madge, Ph.D
Vice President, Research Service Division
Over 20 years’ experience working within academia, biotech and CROs. Former VP Research at
Xention, founder of NCE Discovery (now Domainex) and a member of the integrated biomedical
research group at University College London. Dave started his career at the Wellcome
Foundation and received his Ph.D in Chemistry from Imperial College, London.